Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the
 prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed
 solid tumors who will be treated with a chemotherapy regimen that includes cisplatin. The
 study will evaluate the investigational drug for the treatment of CINV during the first cycle
 of treatment with cisplatin.
Inclusion Criteria:

 -  Patient is greater than 18 years of age.

 -  Patient is scheduled to receive his/her first

 course of cisplatin chemotherapy for a solid tumor.

 -  Patient has a prognosis (life expectancy) greater than or equal to 3 months.